Strategic CDMO Tedor Pharma Services operates as a science-driven CDMO offering drug development, analytical testing, and manufacturing, with capabilities spanning regulatory filing and cGMP manufacturing, presenting upsell opportunities across end-to-end development and commercial services.

Specialized Capabilities Focus on DEA-scheduled products I-V, high potency formulations, powder biologics, small batch manufacturing, and orphan drugs suggests targeted cross-sell potential to customers needing specialized, compliant, and regulated manufacturing and packaging solutions.

Growth & Hiring Recent leadership appointment in business development and a revenue range of 25–50 million indicate an active expansion posture and a ripe window for strategic partnerships, channel partnerships, and expanded service footprints.

Global Quality Footprint Comprehensive capabilities in quality assurance, regulatory filing, and legal compliance position Tedor as a reliable partner for clients aiming to accelerate regulatory approvals and reduce development timelines.

Mid-market Target With 11–50 employees and competitive benefits in a niche CDMO space, Tedor can be positioned as a flexible, customer-centric partner for small-to-mid-sized pharma and biotech companies seeking scalable outsourcing with high customization.